- Home
- Companies
- Sanuwave and Sanuwave Health, Inc.
- Products
- SANUWAVE BIOVANCE - Advanced Wound Care ...
SANUWAVE BIOVANCE - Advanced Wound Care Solution
Derived from the human placenta with unique properties, BIOVANCE® Human Amniotic Membrane Allograft incorporates into wounded tissue to support the body’s normal ability to heal. As decellularized, dehydrated human amniotic membrane (DDHAM) derived from the placenta, BIOVANCE is an intact, natural extracellular matrix (ECM) that acts as a wound covering that allows cellular attachment and growth factor storage. Amnion is unique in its capacity to support human growth and development. The placenta-derived components in BIOVANCE contain key ECM proteins to support the repair of damaged tissue when applied to a wound.
BIOVANCE is prepared from the human amnion of a healthy, full-term pregnancy. The amnion is excised from the chorion layer of the placenta, washed, and then sterilized so that it contains only what’s needed to function as a wound covering and support the body’s ability to heal.

Easy Application
- No preparation of BIOVANCE needed: No thawing, rinsing, or soaking required prior to use
- Flexible form: Conforms easily to irregular surfaces
- Bidirectional orientation: Prevents the need for specific placement of BIOVANCE on the wound; can be applied with either side facing the wound
- Adheres without sutures: Can be fastened by all surgical means if physician chooses to do so
Convenient Storage
- Ambient room-temperature storage in a clean, dry environment: No refrigeration necessary
- Ten-year shelf life: Eliminates the need for preordering
Minimal Processing
- The tissue contains no antigens,7 which further minimizes the risk of inflammatory response.
- Tissue derived from the amniotic membrane is cleaned and preserved without altering its native matrix architecture.
Quality Assurance
Tissue used in processing BIOVANCE:
- Has been procured, processed, and tested in accordance with standards established by the American Association of Blood Banks (AABB) and the United States Food and Drug Administration (FDA).
- Is tested for toxicity, hemolysis, irritation, endotoxins, and pyrogenicity. Current testing cannot provide absolute assurance that the tissue will not transmit infectious diseases to the patient.
- Utilizes a bar-code tracking system for monitoring. It is the responsibility of the practitioner to maintain sufficient records to permit prompt identification of the recipient.